Vivaldis Vetecto Chewable Tablets for Dogs | Afoxolaner Isoxazoline | Tick & Flea Treatment | 250mg / 500mg / 1000mg / 1400mg

VETERINARY PRESCRIPTION RECOMMENDED. For use in dogs only. Administer as directed by a veterinarian. Do not use in cats. Keep out of reach of children. Store in a cool, dry place away from direct sunlight.

Vivaldis Vetecto Chewable Tablets for Dogs | Afoxolaner Isoxazoline Ectoparasiticide

Vivaldis Vetecto is an oral chewable ectoparasiticide for dogs containing Afoxolaner — an isoxazoline-class systemic insecticide and acaricide. Vetecto kills fleas and ticks by systemic distribution via the bloodstream, eliminating ectoparasites when they bite the treated dog. Available in four weight-based strengths (250mg, 500mg, 1000mg, 1400mg) to ensure accurate dose delivery across small, medium, large, and extra-large breeds. A single monthly oral dose provides sustained tick and flea protection for up to 30 days. The chewable tablet format eliminates the need for topical spot-on application, avoiding coat residue, skin sensitivity at application sites, and environmental transfer concerns.

Composition

• Afoxolaner: dose-specific per tablet (250mg / 500mg / 1000mg / 1400mg)
• Excipients: as per label (chewable tablet base)

Drug Class

• Veterinary ectoparasiticide — Isoxazoline class — Afoxolaner — systemic insecticide and acaricide — tick and flea treatment and prevention — dogs

Mechanism of Action

• GABA-gated chloride channel antagonism (invertebrate-selective): Afoxolaner is an isoxazoline compound that acts as a potent antagonist at GABA (gamma-aminobutyric acid)-gated chloride channels (GABA−Cl− channels) and glutamate-gated chloride channels (GluCl channels) in invertebrate nervous systems; in insects (fleas) and arachnids (ticks), GABAergic interneurons provide inhibitory control of motor neuron excitability via GABAR-mediated Cl− influx (membrane hyperpolarisation); Afoxolaner blocks GABA-gated Cl− influx at insect/arachnid GABAα receptor subtypes — specifically at the picrotoxin-binding site within the chloride channel pore (distinct from benzodiazepine and barbiturate sites on vertebrate GABA−A receptors); channel blockade prevents Cl− influx → sustained membrane depolarisation of motor neurons → uncontrolled neuronal excitation → uncoordinated muscle contractions, paralysis, and death of the ectoparasite; Afoxolaner also antagonises invertebrate glutamate-gated Cl− channels (GluCl — expressed in invertebrate neuromuscular junctions, absent in vertebrates), compounding its ectoparasiticide activity; the selectivity of Afoxolaner for invertebrate vs. mammalian GABA-A receptors is the pharmacological basis for its wide safety margin in dogs — mammalian GABA-A receptors have distinct subunit composition (primarily α/β/γ heteromers with benzodiazepine-sensitive γ subunits) with low isoxazoline sensitivity at therapeutic doses; CNS penetration in mammals is also limited by P-glycoprotein (P-gp/MDR1) efflux at the blood-brain barrier — dogs with MDR1/ABCB1 loss-of-function mutations (Collies, Australian Shepherds, Shelties, Border Collies) may have reduced CNS efflux and should be used with veterinary caution at standard doses
• Pharmacokinetics in dogs: Afoxolaner is highly lipophilic; oral bioavailability is enhanced when administered with food; peak plasma concentration reached within 2–4 hours post-dose; extensively plasma-protein bound (>99%); volume of distribution high (extensive tissue distribution); terminal half-life approximately 14–15 days in dogs — provides sustained plasma concentrations above ectoparasiticidal threshold for ≥30 days from a single dose; minimal hepatic metabolism; primarily excreted via faeces; concentrations in blood (plasma) are sufficient to kill fleas within 8–12 hours and ticks within 24–48 hours of attachment after a single dose
• Spectrum of activity — ticks: Ixodes ricinus (European castor bean tick — Lyme disease, Anaplasmosis, Babesiosis vector), Ixodes scapularis, Rhipicephalus sanguineus (brown dog tick — Ehrlichiosis, Babesia canis vector), Amblyomma americanum (lone star tick), Haemaphysalis spp. (relevant in India — Kyasanur Forest Disease vector); adult and nymphal ticks killed within 24–48 hours of attachment (before sufficient feeding time for most pathogen transmission)
• Spectrum of activity — fleas: Ctenocephalides felis (cat flea — primary flea species infesting dogs in India) and Ctenocephalides canis (dog flea); adult fleas killed within 8–12 hours; also disrupts flea reproduction by killing newly acquired fleas before egg laying; reduces environmental flea burden over time with monthly use

Indications

• Treatment and prevention of tick infestations (Ixodes, Rhipicephalus, Amblyomma, Haemaphysalis spp.) in dogs
• Treatment and prevention of flea infestations (Ctenocephalides felis, C. canis) in dogs
• Prevention of tick-borne diseases (Ehrlichiosis, Babesiosis, Lyme disease, Anaplasmosis) by rapid tick kill before pathogen transmission
• Monthly ectoparasite prevention in dogs in tick and flea-endemic regions

Dosage & Administration

• 250mg — for dogs up to approximately 5.4kg
• 500mg — for dogs approximately 5.5–10kg
• 1000mg — for dogs approximately 10–25kg
• 1400mg — for dogs approximately 25–50kg
• Administer orally once monthly; administer with food to maximise absorption
• Confirm weight-appropriate dosing with a veterinarian before administration

Contraindications & Safety

• Do not use in cats
• Do not use in puppies under 8 weeks of age or under 2kg body weight
• Use with caution in dogs with a history of seizures or neurological disorders
• Use with veterinary caution in MDR1/ABCB1-deficient breeds (Collies, Australian Shepherds, Shelties, Border Collies, Whippets)
• Safe to use in breeding, pregnant, and lactating dogs at recommended doses (confirm with veterinarian)
• Most common adverse effects: vomiting, diarrhoea, lethargy (transient); administer with food to reduce GI effects
• Store in a cool, dry place; keep out of reach of children